Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study

BackgroundIn real-world studies, it is unclear whether galcanezumab has a significant effect in the first week after administration.MethodsWe retrospectively assessed 55 high-frequency episodic migraine (HFEM) and chronic migraine patients who received three galcanezumab doses. Mean changes in the numbers of weekly migraine days (WMDs) during month 1 and migraine days per month (MMDs) after 1-3 months of treatment were obtained. Clinical factors related to a >= 50% response rate (RR) at month 3 were analyzed. The prediction of >= 50% responders at month 3 using different weekly RRs at week 1 (W1) was evaluated. The RR at W1 was calculated with the following formula: RR (%) = 100 - [(WMDs at W1/baseline WMD) x 100].ResultsThe number of MMDs significantly improved from baseline to 1, 2 and 3 months. The >= 50% RR was 50.9% at 3 months. The number of WMDs decreased significantly from baseline to week 1 (- 1.6 +/- 1.7 days), week 2 (- 1.2 +/- 1.6 days), week 3 (- 1.0 +/- 1.3 days), and week 4 (- 1.1 +/- 1.6 days) during month 1. The RR at W1 was largest (44.6 +/- 42.2%). The >= 30%, >= 50% and >= 75% RRs at W1 were significantly predictive of a >= 50% RR at 3 months. Logistic regression analysis predicting a >= 50% RR at month 3 showed that the RR at W1 was the sole contributing factor.ConclusionIn our study, galcanezumab showed a significant effect in the first week after administration, and the RR at W1 could predict the RR at 3 months.

Automated summary

This study retrospectively assessed the effect of galcanezumab in the first week after administration and found that it had a significant effect. The number of weekly migraine days and monthly migraine days significantly improved after 1-3 months of treatment. Additionally, the response rate at week 1 could predict the response rate at 3 months.